We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » COVID-19

COVID-19
%{topic} RSS Feed RSS

Biden Doubles COVID-19 Vaccination Goal

March 26, 2021
In his first presidential news conference yesterday, President Biden set a new goal of 200 million COVID-19 vaccinations by his 100th day in office — doubling his initial goal. Read More

AstraZeneca’s COVID-19 Vaccine Continues to Face Issues as EMA Set to Meet Again Over Blood Clots

March 26, 2021
AstraZeneca (AZ) responded to National Institutes of Health (NIH) concerns over its interim vaccine trial data by releasing its primary analysis results yesterday, but the embattled company’s two-dose shot faces intense scrutiny, with the European Medicines Agency (EMA) holding an expert meeting on March 29 to review possible links to blood clots. Read More
CE mark

Novacyt Earns CE Mark for COVID-19 Variant Test

March 26, 2021
The assay panel returns results in under two hours. Read More
emergency use authorization approved

Beckman Coulter Receives FDA EUA for COVID-19 IgG Antibody Test

March 26, 2021
The test, which has also been cleared in Europe, is run on the company’s immunoassay analyzers, including its DxI 800 system, which can process up to 4,800 samples daily. Read More

Cancer Drugs Remain the Focus of Developers, but Pandemic Sees Large Spike in Anti-Infectives

March 25, 2021
A new report analyzing drug research and development (R&D) during the pandemic found that while cancer drugs have remained industry’s top focus, anti-infective drugs saw the biggest increase of all therapies due to the monumental efforts to combat the COVID-19 crisis. Read More

J&J Promises to Deliver 20 Million Covid-19 Vaccine Doses by Next Week

March 25, 2021
Johnson & Johnson (J&J) said it expects to deliver 20 million doses of its COVID-19 vaccine for the U.S. by the end of March, as officials nationwide continued to complain of severely limited supplies of the single-shot vaccine. Read More

European Commission Moves Forward on Tightening Vaccine Exports

March 25, 2021
As Europe continues to face challenges and setbacks in its COVID-19 vaccination efforts, the European Commission (EC) has proposed new criteria for vaccine export authorizations to conserve its supplies. Read More

Russia Pursues Single-Dose, Light Version of Sputnik V Vaccine

March 24, 2021
Russian researchers are reportedly seeking approval for a single-dose version of the Sputnik V COVID-19 vaccine and are conducting clinical trials in Russia, the United Arab Emirates and Ghana. Read More

COVAX Will Hold Back 5 Percent of Vaccine Doses for Emergencies

March 24, 2021
The COVAX vaccine-sharing program will stockpile 5 percent of its vaccine doses for high-risk populations in humanitarian settings or for emergency outbreaks, said Gavi, the Vaccine Alliance, which operates the global program alongside the World Health Organization and the Coalition for Epidemic Preparedness Innovations. Read More

Regeneron/Roche COVID-19 Antibody Cocktail Cuts Hospitalizations and Deaths

March 24, 2021
Regeneron Pharmaceuticals’ and Roche’s antibody cocktail, REGEN-COV (casirivimab/imdevimab), reduced the risk of hospitalization or death by 70 percent in high-risk nonhospitalized COVID-19 patients in a late-stage trial, the companies have said. Read More

Pfizer Launches Phase 1 Trial for Oral COVID-19 Antiviral

March 24, 2021
Pfizer is conducting a U.S. phase 1 trial of an oral COVID-19 antiviral, PF-07321332, a protease inhibitor that can stop the virus from replicating. An oral drug would be much easier to administer than an intravenous formulation — a significant advantage during the pandemic. Read More

CDER’s Office of Compliance Reports on its Activities in 2020

March 24, 2021
The Center for Drug Evaluation and Research (CDER) highlights efforts to deal with drug shortages, sham COVID-19 products and poorly compounded drugs, as well as its enforcement successes amidst the pandemic, in its latest annual report from its Office of Compliance, released yesterday. Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 136 137 Next

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • EMA logo European Medicines Agency logo

    EMA Reviews GSK’s and Vir’s VIR-7831 for COVID-19

  • CE mark

    Hensler Surgical Technologies Earns CE Mark for Bone-Fusion Device

  • Eli lilly logo

    Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

  • CE mark

    Alimetry Earns CE Mark for Wearable Gastric Disease Diagnostic

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing